Description
R-Equol is the diasteromer of S-Equol. Although S-equol is a naturally occuring isoflavone metabolite in humans, R-equol is not. However, both of these diasteromers are biologically active.
| Product Unit Size | Cost | Quantity | Stock |
|---|
R-Equol is the diasteromer of S-Equol. Although S-equol is a naturally occuring isoflavone metabolite in humans, R-equol is not. However, both of these diasteromers are biologically active.
| Cas No. | 221054-79-1 |
|---|---|
| Purity | ≥98% |
| Formula | C15H14O3 |
| Formula Wt. | 242.27 |
| Chemical Name | (3R)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol |
| IUPAC Name | (3R)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol |
| Synonym | (3R)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Lephart E. Resveratrol, 4’ acetoxy resveratrol, R-equol, racemic equol or S-equol as cosmeceuticals to improve dermal health. Int J Mol Sci. 2017 Jun 3;18(6):1193. PMID: 28587197
Setchell K, Zhao X, Jha P, et al. The pharmacokinetic behavios of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers. Am J Clin Nutr. 2009 Oct;90(4):1029-1037. PMID: 19710188
AT-II antagonist, PPARγ/δ modulator.
FLT3, PDGFR inhibitor.
Polypeptide; serine protease inhibitor.
MGMT inhibitor.
Endogenous glycoprotein; lactoferrin agonist.
TLR7 agonist
Endogenous peptide, involved in paracrine and a...
CDK inhibitor, L-type Ca2+ channel blocker.
Expectorant.
Binds to neurotoxin receptor site 2 on voltage-...
NSAID; COX-1/2 inhibitor.
Calcium channel blocker.
Found in Aconitum bulleyanum; voltage-gated Na+...
PP2A activator, Sphk1 and PKC inhibitor.
Mesalazine derivative, sulfa drug; sepiapterin ...
Endogenous neuropeptide, involved in opioid sig...
Protonophore; chitinase OvCHT1 inhibitor.
Mycotoxin produced by Fusarium; sphingosine acy...
Endogenous tachykinin peptide, involved in infl...
Triterpenoid